Sarah P. Psutka, MD, discusses the efficacy of the combination of immune checkpoint inhibitor therapy plus tyrosine kinase inhibitor for the treatment of metastatic renal cell carcinoma.
Sarah P. Psutka, MD, a urologic oncologist and associate professor in the Department of Urology at the University of Washington Medical Center, discusses the efficacy of the combination of immune checkpoint inhibitor (ICI) therapy plus tyrosine kinase inhibitor (TKI) for the treatment of metastatic renal cell carcinoma.
According to Psutka, the retrospective study looked at 85 patients, 33 of which received frontline immunotherapy or ICI plus TKI. The remaining 52 received this combination in the salvage setting. The overall response rate in the frontline setting was found to 56.7% and 37.5% in the second-line setting. The median progression-free survival (PFS) was 15.2 months in the frontline setting and 14.2 months in the second-line setting.
The combination was found to be safe, with grade 3 or higher adverse events occurring in 52% of patients. Additionally, according to Psutka, patients who received immunotherapy in the frontline setting had a higher objective response rate.
0:08 | This was a study of 85 patients of whom 33 patients received frontline immunotherapy or ICI plus TKI, and 52 patients received this combination therapy in the salvage setting. Our objective response rates with combination ICI-TKI therapy were 56.7% in the frontline setting and then 37.5% overall in the second line setting. PFS was 15.2 months in the frontline setting, compared to 14.2 months in the second line setting.
0:45 | First with respect to safety. In general, this was the second line or salvage utilization of ICI-TKI therapy in this study, appeared to be safe. The grade 3 or greater adverse event rate was 52%. Within that occurred in 25, out of the 52 patients. The objective response rates in patients who were TKI naive in the salvage setting appeared to be the highest. So, patients for example, who'd received ipilimumab [Yervoy] plus nivolumab [Opdivo] as their frontline therapy, those patients had a much higher objective response rate when treated with the combination ICI or IO, TKI therapy in the salvage setting within an objective response rate of 50% and median progression free survival in that group of 9.1 months. And then obviously, we noted as patients were treated with subsequent lines of therapy, the objective response rates and PFS length decreased with each subsequent line of therapy, which is similar to what's been reported previously in the literature.
George Discusses Potency of VEGF TKIs in Advanced Renal Cell Carcinoma
March 22nd 2024During a Case-Based Roundtable® event, Saby George, MD, discussed the case of a patient with clear cell renal cell carcinoma who progressed after left nephrectomy followed by treatment with axitinib plus pembrolizumab at recurrence.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Evolving Evidence Guides Treatment Selection for Favorable-Risk mRCC
March 6th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Rana McKay, MD, moderated a discussion on key takeaways from frontline combination trial data in patients with metastatic renal cell carcinoma. This is the second of 2 articles based on this event.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Guideline Recommendation Favors Doublet Over Triplet Therapy in ccRCC
February 28th 2024New guideline favors doublet therapy over triplet for metastatic renal clear cell cancer due to lower toxicity. COSMIC-313 trial shows improved progression-free survival with triplet therapy but significant adverse events.
Read More
Risk Groups Vital to Interpreting Results of RCC Immunotherapy Trials
February 21st 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Robert J. Motzer, MD, examined the impact of the CheckMate 214 and CheckMate 9ER trials of nivolumab/ipilimumab and nivolumab/cabozantinib in patients with advanced renal cell carcinoma. This is the first of 2 articles based on this event.
Read More